<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34592944</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2288</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>BMC medical research methodology</Title><ISOAbbreviation>BMC Med Res Methodol</ISOAbbreviation></Journal><ArticleTitle>Joint latent class model: Simulation study of model properties and application to amyotrophic lateral sclerosis disease.</ArticleTitle><Pagination><StartPage>198</StartPage><MedlinePgn>198</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">198</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12874-021-01377-9</ELocationID><Abstract><AbstractText Label="BACKGROUND">In many clinical applications, evolution of a longitudinal marker is censored by an event occurrence, and, symmetrically, event occurrence can be influenced by the longitudinal marker evolution. In such frameworks joint modeling is of high interest. The Joint Latent Class Model (JLCM) allows to stratify the population into groups (classes) of patients that are homogeneous both with respect to the evolution of a longitudinal marker and to the occurrence of an event; this model is widely employed in real-life applications. However, the finite sample-size properties of this model remain poorly explored.</AbstractText><AbstractText Label="METHODS">In the present paper, a simulation study is carried out to assess the impact of the number of individuals, of the censoring rate and of the degree of class separation on the finite sample size properties of the JLCM. A real-life application from the neurology domain is also presented. This study assesses the precision of class membership prediction and the impact of covariates omission on the model parameter estimates.</AbstractText><AbstractText Label="RESULTS">Simulation study reveals some departures from normality of the model for survival sub-model parameters. The censoring rate and the number of individuals impact the relative bias of parameters, especially when the classes are weakly distinguished. In real-data application the observed heterogeneity on individual profiles in terms of a longitudinal marker evolution and of the event occurrence remains after adjusting to clinically relevant and available covariates; CONCLUSION: The JLCM properties have been evaluated. We have illustrated the discovery in practice and highlights the usefulness of the joint models with latent classes in this kind of data even with pre-specified factors. We made some recommendations for the use of this model and for future research.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kyheng</LastName><ForeName>Ma&#xe9;va</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>ULR 2694 - METRICS : &#xe9;valuation des technologies de sant&#xe9; et des pratiques m&#xe9;dicales, Univ. Lille, CHU Lille, Lille, France. m.kyheng.chr@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>D&#xe9;partement de Biostatistiques, CHU Lille, Lille, France. m.kyheng.chr@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Babykina</LastName><ForeName>G&#xe9;nia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>ULR 2694 - METRICS : &#xe9;valuation des technologies de sant&#xe9; et des pratiques m&#xe9;dicales, Univ. Lille, CHU Lille, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>D&#xe9;partement de Biostatistiques, CHU Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ternynck</LastName><ForeName>Camille</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>ULR 2694 - METRICS : &#xe9;valuation des technologies de sant&#xe9; et des pratiques m&#xe9;dicales, Univ. Lille, CHU Lille, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>D&#xe9;partement de Biostatistiques, CHU Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devos</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Expert center for ALS, Expert center for Parkinson, Medical Pharmacology, Univ. Lille, Lille Neuroscience &amp; Cognition, Inserm, UMR-S1172, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Labreuche</LastName><ForeName>Julien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Expert center for ALS, Expert center for Parkinson, Medical Pharmacology, Univ. Lille, Lille Neuroscience &amp; Cognition, Inserm, UMR-S1172, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duhamel</LastName><ForeName>Alain</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ULR 2694 - METRICS : &#xe9;valuation des technologies de sant&#xe9; et des pratiques m&#xe9;dicales, Univ. Lille, CHU Lille, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>D&#xe9;partement de Biostatistiques, CHU Lille, Lille, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med Res Methodol</MedlineTA><NlmUniqueID>100968545</NlmUniqueID><ISSNLinking>1471-2288</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015982" MajorTopicYN="N">Bias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003198" MajorTopicYN="N">Computer Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015233" MajorTopicYN="N">Models, Statistical</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Joint model</Keyword><Keyword MajorTopicYN="N">Latent classes</Keyword><Keyword MajorTopicYN="N">Linear mixed model</Keyword><Keyword MajorTopicYN="N">MLE properties</Keyword><Keyword MajorTopicYN="N">Monte Carlo simulations</Keyword><Keyword MajorTopicYN="N">Survival analysis</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>1</Day><Hour>5</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34592944</ArticleId><ArticleId IdType="pmc">PMC8482570</ArticleId><ArticleId IdType="doi">10.1186/s12874-021-01377-9</ArticleId><ArticleId IdType="pii">10.1186/s12874-021-01377-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rizopoulos D. Joint models for longitudinal and time-to-event data: With applications in R. London: Chapman &amp; Hall; 2012.</Citation></Reference><Reference><Citation>Wulfsohn MS, Tsiatis AA. A joint model for survival and longitudinal data measured with error. Biometrics. 1997;53:330&#x2013;9. doi: 10.2307/2533118.</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2533118</ArticleId><ArticleId IdType="pubmed">9147598</ArticleId></ArticleIdList></Reference><Reference><Citation>Verbeke G, Lesaffre E. A linear mixed-effects model with heterogeneity in the random-effects population. J Am Stat Assoc. 1996;91(433):217&#x2013;21. doi: 10.1080/01621459.1996.10476679.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01621459.1996.10476679</ArticleId></ArticleIdList></Reference><Reference><Citation>Muth&#xe9;n B, Shedden K. Finite mixture modeling with mixture outcomes using the em algorithm. Biometrics. 1999;55(2):463&#x2013;9. doi: 10.1111/j.0006-341X.1999.00463.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0006-341X.1999.00463.x</ArticleId><ArticleId IdType="pubmed">11318201</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H, Turnbull BW, McCulloch CE, Slate EH. Latent class models for joint analysis of longitudinal biomarker and event process data: application to longitudinal prostate-specific antigen readings and prostate cancer. J Am Stat Assoc. 2002;97(457):53&#x2013;65. doi: 10.1198/016214502753479220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1198/016214502753479220</ArticleId></ArticleIdList></Reference><Reference><Citation>Proust-Lima C, Dartigues J-F, Jacqmin-Gadda H. Joint modeling of repeated multivariate cognitive measures and competing risks of dementia and death: a latent process and latent class approach. Stat Med. 2016;35(3):382&#x2013;98. doi: 10.1002/sim.6731.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.6731</ArticleId><ArticleId IdType="pubmed">26376900</ArticleId></ArticleIdList></Reference><Reference><Citation>Proust-Lima C, S&#xe9;ne M, Taylor JM, Jacqmin-Gadda H. Joint latent class models for longitudinal and time-to-event data: A review. Stat Methods Med Res. 2014;23(1):74&#x2013;90. doi: 10.1177/0962280212445839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0962280212445839</ArticleId><ArticleId IdType="pmc">PMC5863083</ArticleId><ArticleId IdType="pubmed">22517270</ArticleId></ArticleIdList></Reference><Reference><Citation>Syrj&#xe4;l&#xe4; E, Nevalainen J, Peltonen J, Takkinen H-M, Hakola L, &#xc5;kerlund M, Veijola R, Ilonen J, Toppari J, Knip M, Virtanen SM. A joint modeling approach for childhood meat, fish and egg consumption and the risk of advanced islet autoimmunity. Sci Rep. 2019;9(1):7760. doi: 10.1038/s41598-019-44196-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-44196-1</ArticleId><ArticleId IdType="pmc">PMC6533366</ArticleId><ArticleId IdType="pubmed">31123290</ArticleId></ArticleIdList></Reference><Reference><Citation>Brilleman SL, Moreno-Betancur M, Polkinghorne KR, McDonald SP, Crowther MJ, Thomson J, Wolfe R. Changes in body mass index and rates of death and transplant in hemodialysis patients: a latent class joint modeling approach. Epidemiology. 2019;30(1):38&#x2013;47. doi: 10.1097/EDE.0000000000000931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0000000000000931</ArticleId><ArticleId IdType="pubmed">30499863</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogata S, Watanabe M, Kokubo Y, Higashiyama A, Nakao YM, Takegami M, Nishimura K, Nakai M, Kiyoshige E, Hosoda K, Okamura T, Miyamoto Y. Longitudinal trajectories of fasting plasma glucose and risks of cardiovascular diseases in middle age to elderly people within the general Japanese population: the Suita Study. J Am Heart Assoc. 2019;8(3):010628. doi: 10.1161/JAHA.118.010628.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.118.010628</ArticleId><ArticleId IdType="pmc">PMC6405575</ArticleId><ArticleId IdType="pubmed">30686107</ArticleId></ArticleIdList></Reference><Reference><Citation>Portegies MLP, Mirza SS, Verlinden VJA, Hofman A, Koudstaal PJ, Swanson SA, Ikram MA. Mid-to late-life trajectories of blood pressure and the risk of stroke: the Rotterdam Study. Hypertension (Dallas, Tex.: 1979) 2016;67(6):1126&#x2013;32. doi: 10.1161/HYPERTENSIONAHA.116.07098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.116.07098</ArticleId><ArticleId IdType="pubmed">27160196</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang G, Luk AOY, Tam CHT, Xie F, Carstensen B, Lau ESH, Lim CKP, Lee HM, Ng ACW, Ng MCY, Ozaki R, Kong APS, Chow CC, Yang X, Lan H-Y, Tsui SKW, Fan X, Szeto CC, So WY, Chan JCN, Ma RCW, Hong Kong Diabetes Register TRS Study Group Progression of diabetic kidney disease and trajectory of kidney function decline in Chinese patients with Type 2 diabetes. Kidney Int. 2019;95(1):178&#x2013;87. doi: 10.1016/j.kint.2018.08.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2018.08.026</ArticleId><ArticleId IdType="pubmed">30415941</ArticleId></ArticleIdList></Reference><Reference><Citation>Marioni RE, Proust-Lima C, Amieva H, Brayne C, Matthews FE, Dartigues J-F, Jacqmin-Gadda H. Cognitive lifestyle jointly predicts longitudinal cognitive decline and mortality risk. Eur J Epidemiol. 2014;29(3):211&#x2013;9. doi: 10.1007/s10654-014-9881-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-014-9881-8</ArticleId><ArticleId IdType="pmc">PMC4003346</ArticleId><ArticleId IdType="pubmed">24577561</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin Y, Tian Y, Han H, Liu L, Ge X, Xue H, Wang T, Zhou L, Liang R, Yu H. Risk classification for conversion from mild cognitive impairment to Alzheimer&#x2019;s disease in primary care. Psychiatry Res. 2019;278:19&#x2013;26. doi: 10.1016/j.psychres.2019.05.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psychres.2019.05.027</ArticleId><ArticleId IdType="pubmed">31132572</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamenic D, Rousseau A, Essig M, Gatault P, Buchler M, Filloux M, Marquet P, Pr&#xe9;maud A. A prognostic tool for individualized prediction of graft failure risk within ten years after kidney transplantation. J Transplant. 2019;2019:7245142. doi: 10.1155/2019/7245142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/7245142</ArticleId><ArticleId IdType="pmc">PMC6476124</ArticleId><ArticleId IdType="pubmed">31093367</ArticleId></ArticleIdList></Reference><Reference><Citation>Proust-Lima C, Joly P, Dartigues J-F, Jacqmin-Gadda H. Joint modelling of multivariate longitudinal outcomes and a time-to-event: a nonlinear latent class approach. Comput Stat Data Anal. 2009;53(4):1142&#x2013;54. doi: 10.1016/j.csda.2008.10.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csda.2008.10.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer L, Rondeau V, Dignam J, Pickles T, Jacqmin-Gadda H, Proust-Lima C. Joint modelling of longitudinal and multi-state processes: application to clinical progressions in prostate cancer. Stat Med. 2016;35(22):3933&#x2013;48. doi: 10.1002/sim.6972.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.6972</ArticleId><ArticleId IdType="pmc">PMC5012926</ArticleId><ArticleId IdType="pubmed">27090611</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouanet A, Joly P, Dartigues J-F, Proust-Lima C, Jacqmin-Gadda H. Joint latent class model for longitudinal data and interval-censored semi-competing events: Application to dementia. Biometrics. 2016;72(4):1123&#x2013;35. doi: 10.1111/biom.12530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/biom.12530</ArticleId><ArticleId IdType="pubmed">27123856</ArticleId></ArticleIdList></Reference><Reference><Citation>Commenges D, Jacqmin-Gadda H. Mod&#xe8;les Biostatistiques Pour L&#x2019;&#xe9;pid&#xe9;miologie. France: De Boeck Superieur; 2015.</Citation></Reference><Reference><Citation>Proust C, Jacqmin-Gadda H. Estimation of linear mixed models with a mixture of distribution for the random effects. Comput Methods Prog Biomed. 2005;78(2):165&#x2013;73. doi: 10.1016/j.cmpb.2004.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmpb.2004.12.004</ArticleId><ArticleId IdType="pmc">PMC1913221</ArticleId><ArticleId IdType="pubmed">15848271</ArticleId></ArticleIdList></Reference><Reference><Citation>Tofighi D, Enders CK. Identifying the correct number of classes in growth mixture models. Adv Latent Variable Mixture Model. 2008;2007:317&#x2013;41.</Citation></Reference><Reference><Citation>Babykina G, Couallier V. Empirical assessment of the maximum likelihood estimator quality in a parametric counting process model for recurrent events. Comput Stat Data Anal. 2012;56(2):297&#x2013;315. doi: 10.1016/j.csda.2011.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csda.2011.08.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Sirvanci M, Yang G. Estimation of the weibull parameters under type i censoring. J Am Stat Assoc. 1984;79(385):183&#x2013;7. doi: 10.1080/01621459.1984.10477082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01621459.1984.10477082</ArticleId></ArticleIdList></Reference><Reference><Citation>Yates E, Rafiq M. Prognostic factors for survival in patients with amyotrophic lateral sclerosis: analysis of a multi-centre clinical trial. J Clin Neurosci. 2016;32:51&#x2013;6. doi: 10.1016/j.jocn.2015.12.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2015.12.037</ArticleId><ArticleId IdType="pubmed">27401224</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, Traynor BG, Consortium E, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10(5-6):310&#x2013;23. doi: 10.3109/17482960802566824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960802566824</ArticleId><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinman L, Cudkowicz M. Emerging targets and treatments in amyotrophic lateral sclerosis. Lancet Neurol. 2011;10(5):481&#x2013;90. doi: 10.1016/S1474-4422(11)70024-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(11)70024-2</ArticleId><ArticleId IdType="pubmed">21511200</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenglet T, Lacomblez L, Abitbol J, Ludolph A, Mora J, Robberecht W, Shaw P, Pruss R, Cuvier V, Meininger V, et al. A phase II- III trial of olesoxime in subjects with amyotrophic lateral sclerosis. Eur J Neurol. 2014;21(3):529&#x2013;36. doi: 10.1111/ene.12344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12344</ArticleId><ArticleId IdType="pubmed">24447620</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disorders. 2000;1(5):293&#x2013;9. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>